ArticleBlood advances2021

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.

Anthony M Hunter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.